Pharmacodynamic and Pharmacokinetic Features of Cabergoline

  title={Pharmacodynamic and Pharmacokinetic Features of Cabergoline},
  author={Ruggero G. Fariello},
SummaryThe appearance of late motor complications is the major drawback of long term levodopa therapy in patients with Parkinson’s disease. Although disease progression may be a factor in the aetiology of these complications, unfavourable properties of levodopa may promote their development. These include competition with amino acids for gastrointestinal absorption and passage through the blood-brain barrier; and a short duration of action with a rapid peak plasma concentration and rapid… 
Pharmacological therapy of Parkinson's disease: current options and new avenues.
The aim of this review is to summarize the features of drugs currently used in the pharmacotherapy of Parkinson's disease, with a look at their beneficial effects and limitations.
Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin
Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia.
BL-1023 improves behavior and neuronal survival in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-intoxicated mice
Select abilities of BL-1023 to increase dopaminergic neuronal survival and improve motor function in MPTP-mice are demonstrated.
In-vitro dissolution rate and molecular docking studies of cabergoline drug with β-cyclodextrin
Abstract The physicochemical properties and dissolution profile of cabergoline drug (CAB) with β-cyclodextrin (β-CD) inclusion complex were investigated by the UV spectroscopy. The inclusion complex
Dopamine D2 agonist affects visuospatial working memory distractor interference depending on individual differences in baseline working memory span
Results showed greater interference from distractors under cabergoline, particularly for individuals with higher baseline dopamine (indicated by WM span), which support computational theories of striatal D1–D2 function during WM encoding and distractor-filtering and provide new evidence for interactive cortico-striatal systems that support VSWM capacity and their dependence on WM span.


Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
Pergolide would appear to be at least as useful as other dopamine agonists such as bromocriptine or lisuride for the management of patients with Parkinson's disease when administered in combination with levodopa.
Cabergoline in the treatment of early parkinson's disease
The results of this study indicate that cabergoline treatment for up to 1 year is only marginally less effective than levodopa in the proportion of patients who can be treated in monotherapy.
Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
It is confirmed that cabergoline is effective in the management of PD motor fluctuations without modifying L-dopa and 3-OMD pharmacokinetics.
A rationale for dopamine agonists as primary therapy for Parkinson's disease.
  • C. Olanow
  • Medicine
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • 1992
Levodopa sparing strategies designed to minimize the cumulative levodopa dosage employed over the course of the disease seem a rational way to treat Parkinson patients in face of current information.
Motor complications associated with chronic levodopa therapy in Parkinson's disease.
Patients with complex fluctuations are the least likely to improve with slow-release levodopa preparations, and drugs capable of providing a stable dopaminergic stimulation should be particularly useful for preventing the development of motor complications in patients not yet treated.
Bromocriptine lessens the incidence of mortality in L-Dopa-treated parkinsonian patients: Prado-study discontinued
The results imply that combination therapy with bromocriptine should be preferred over L-Dopa monotherapy from the very beginning.
The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport.
Interference with absorption oflevodopa by food and by competition between large neutral amino acids and levodopa for transport from plasma to the brain may be partly responsible for the fluctuating clinical response in patients with Parkinson's disease.
Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
Results are interpreted as indicating l-deprenyl's ability to prevent or retard the degeneration of striatal dopaminergic neurons, the first anti-Parkinson drug having such a property.
Radioimmunoassay for the synthetic ergoline derivative cabergoline in biological fluids.
The plasma concentrations at the steady state in a patient with Parkinson's disease who had received the drug at single oral daily doses of 3, 5 and 7 mg were determined using the assay, validated in terms of reproducibility, precision and accuracy.
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease
It is concluded that cabergoline is an effective adjunct to levodopa for the treatment of PD.